Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
AMCP Nexus 2022
ASCO 2022 - Wrap Up
ASH 2021 - Myelofibrosis
ASH 2021 Systemic Mastocytosis Wrap-Up
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Lung Cancer
Krazati Receives Accelerated FDA Approval for NSCLC with KRASᴳ¹²ᶜ Mutation
FDA Approvals, News & Updates
,
Lung Cancer
February 2023, Vol 14, No 1
On
December 12, 2022
, the FDA accelerated the approval of adagrasib (Krazati; Mirati Therapeutics), a RAS GTPase inhibitor, for adults with locally advanced or metastatic non–small-cell lung cancer (NSCLC) and
KRAS
G12C
mutation (as determined by an FDA-approved test) who have received at least 1 systemic therapy.
Read Article
Keytruda Received FDA Approval for Adjuvant Treatment of NSCLC
FDA Approvals, News & Updates
,
Lung Cancer
February 2023, Vol 14, No 1
On
January 26, 2023
, the FDA approved pembrolizumab (Keytruda; Merck), a PD-1 inhibitor, as monotherapy for adjuvant treatment of patients with stage IB (T2a ≥4 cm), II, or IIIA non–small-cell lung cancer (NSCLC), after resection and platinum-based chemotherapy.
Read Article
Imjudo FDA Approved with Imfinzi and Chemotherapy for Metastatic NSCLC
FDA Approvals, News & Updates
,
Lung Cancer
December 2022, Vol 13, No 6
Two weeks after the initial approval of tremelimumab (Imjudo; AstraZeneca), a CTLA-4 monoclonal antibody, on
November 10, 2022
, the FDA approved this new immunotherapy, in combination with the PD-L1 inhibitor durvalumab (Imfinzi; AstraZeneca) and platinum-based chemotherapy, for the treatment of adults with metastatic non–small-cell lung cancer (NSCLC) and no
EGFR
or
ALK
genomic alterations.
Read Article
Sotorasib Elicits Durable Responses in Patients with Metastatic NSCLC and KRAS Mutation
By
Phoebe Starr
Lung Cancer
August 2022, Vol 13, No 4 Online Only
Sotorasib (Lumakras) continues to demonstrate durable efficacy in non–small-cell lung cancer (NSCLC) with
KRAS
p.G12C mutation at 2-year follow-up of the phase 2 CodeBreaK 100 clinical trial.
Read Article
Sotorasib Shows Encouraging Activity in Patients with NSCLC and KRAS p.G12C Mutation
By
Phoebe Starr
Lung Cancer
October 2021, Vol 12, No 5
Approximately 13% of patients with lung adenocarcinoma harbor the KRAS p.G12C mutation, which is associated with poor clinical outcomes. During the American Society of Clinical Oncology 2021 virtual annual meeting, Ferdinandos Skoulidis, MD, PhD, MRCP, Assistant Professor, Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, provided updated results from the phase 2 component of the CodeBreaK 100 clinical trial, which evaluated sotorasib (Lumakras), a small-molecule inhibitor of the KRAS p.G12C mutation, in previously treated patients with non–small-cell lung cancer (NSCLC) whose tumors express this aberration. These results were simultaneously published in the New England Journal of Medicine.
Read Article
Neoadjuvant Nivolumab plus Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Resectable NSCLC
By
Phoebe Starr
Lung Cancer
October 2021, Vol 12, No 5
Neoadjuvant nivolumab (Opdivo) plus chemotherapy significantly improved pathologic complete response (pCR) rates versus chemotherapy alone in patients with resectable stage IB-IIIA non–small-cell lung cancer (NSCLC), according to final results from the CheckMate-816 clinical trial. These findings were presented by Patrick Forde, MBBCh, Associate Professor of Oncology and Director of the Thoracic Cancer Clinical Research Program at Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, during the virtual 2021 American Association for Cancer Research Annual Meeting.
Read Article
Exkivity Receives Accelerated Approval for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations
FDA Approvals, News & Updates
,
Lung Cancer
October 2021, Vol 12, No 5
On September 15, 2021, the FDA accelerated the approval of mobocertinib (Exkivity; Takeda Pharmaceuticals), a tyrosine kinase inhibitor, for the treatment of adults with locally advanced or metastatic non−small-cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by the FDA-approved Oncomine Dx Target Test (Life Technologies Corporation), which was approved on the same day as a companion diagnostic for mobocertinib. The FDA granted mobocertinib priority review, breakthrough therapy designation, and orphan drug designation.
Read Article
Atezolizumab Extends Disease-Free Survival in PD-L1−Positive Early-Stage NSCLC
By
Phoebe Starr
ASCO 2021 Highlights
,
Lung Cancer
August 2021, Vol 12, No 4
Treatment with the immune checkpoint inhibitor atezolizumab (Tecentriq) following surgical resection and chemotherapy significantly improved disease-free survival (DFS) compared with best supportive care (BSC) alone in patients with stage II-IIIA non–small-cell lung cancer (NSCLC) and tumor composite score PD-L1 ≥1%, according to interim results from the phase 3 IMpower010 clinical trial, which were presented at the ASCO 2021 virtual annual meeting.
Read Article
Lumakras First FDA-Approved Therapy for Advanced or Metastatic NSCLC with KRAS G12C Mutation
FDA Approvals, News & Updates
,
Lung Cancer
June 2021, Vol 12, No 3
On
May 28, 2021
, the FDA accelerated the approval of sotorasib (Lumakras; Amgen), an oral KRAS inhibitor of the RAS GTPase family, for the treatment of adults with locally advanced or metastatic non–small-cell lung cancer (NSCLC) associated with KRAS G12C mutation, as determined by an FDA-approved test, after ≥1 systemic therapies. The FDA granted sotorasib orphan drug and breakthrough therapy designations.
Read Article
Rybrevant First FDA-Approved Therapy for NSCLC with EGFR Exon 20 Insertion Mutations
FDA Approvals, News & Updates
,
Lung Cancer
June 2021, Vol 12, No 3
On
May 21, 2021
, the FDA accelerated the approval of amivantamab-vmjw (Rybrevant; Janssen/Johnson & Johnson), a bispecific antibody targeting mutations in the
EGFR
and MET pathways, for adults with non–small-cell lung cancer (NSCLC) that is associated with
EGFR
exon 20 insertion mutations, as detected by the FDA-approved Guardant360 CDx test, which was approved on the same day as a companion diagnostic for amivantamab. The FDA had granted amivantamab a breakthrough therapy designation for this indication.
Read Article
Page 1 of 9
1
2
3
4
5
6
7
8
9
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Survey Shows Inflation Affecting Majority of Consumer Healthcare Decisions
2.
Pausing Endocrine Therapy to Become Pregnant Appears Safe for Women with Breast Cancer
Phoebe Starr
3.
New Subgroup Analysis Confirms Efficacy and Safety of Darolutamide Across Different Subgroups of Patients with Metastatic Hormone-Sensitive Prostate Cancer
Anne Rowe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
AMCP Nexus 2022
ASCO 2022 - Wrap Up
ASH 2021 - Myelofibrosis
ASH 2021 Systemic Mastocytosis Wrap-Up
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
VBCC
Print Edition
VBCC
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
VBCC
's
Privacy Policy
, and
VBCC
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION